| 摘要 |
This invention relates to a gene encoding RTVP that has been shown to be up- regulated by p53 using differential display-PCR and subsequently by co- transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis th at was accompanied by increased caspase 8,9 and 3 activities. MRTVP-1-stimulate d apoptosis was also associated with increased levels of bax, bad and activate d BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse mode l of prostate cancer in vivo. These therapeutic activities were associated wit h anti-angiogenic effects and importantly a local and systemic immune response . Accordingly, p53 was linked with suppression of metastasis through its induction of mRTVP-1, which can concurrently induce apoptosis, suppress agiogenesis and stimulate an antitumor immune response. Thus, the invention includes compositions and methods, based on RTVP nucleic acid, polypeptides, and antibodies, for use in the treatment, prevention and detection of neoplastic disease and, specifically, metastatic prostatic neoplasia.</SDOAB >
|
